Search This Blog

Monday, April 20, 2026

Theriva FDA and EMA alignment on proposed pivotal Phase 3 in first-line metastatic pancreatic cancer

 


Theriva Biologics secures FDA and EMA alignment on proposed pivotal Phase 3 trial in first-line metastatic pancreatic cancer

Company to present new VIRAGE Phase 2b VCN-01 data at AACR 2026.

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)